Skip to main content
. 2016 Jun 7;7(29):45687–45701. doi: 10.18632/oncotarget.9920

Figure 5. miR-26a is upregulated by EGFR/Src signaling.

Figure 5

A. qRT-PCR assays of SPCA1 cells after 48h incubation with EGF (10 ng/ml) (a) or 15 μM Gefitinib (b). Data are represented as the mean ± SD of three replicates. ** P<0.01, vs control group. B. Western blot assays of SPCA1 cells after treatment with EGF (10 ng/ml) or Gefitinib (15 μM). C. Western blot assays of SPCA1 cells after treatment with EGF (10 ng/ml) and with or without the Src inhibitor Saracatinib (Sara, 0.5 nM). D. qRT-PCR assays of SPCA1 cells after 48h incubation with or without Sara (0.5 nM) to detect miR-26a expression. Data are represented as the mean ± SD of three replicates. *P<0.05, ** P<0.01, vs control group. E. The IC50 values of Gefitinib for Sara-treated or control cells were measured and plotted as described in Figure 2B and 2D in SPCA1 cells (a) and PC-9 cells (b). Data are represented as the mean ± SD of three replicates. *P<0.05, ** P<0.01, vs control group. In western blot, data are representative of 3 independent experiments. All the protein levels measured with densitometry and normalized to β-actin. Each bar represents the mean±SD from three experiments.*p<0.05, **p<0.01vs control group.